Colgate-Palmolive Company $CL is Sarasin & Partners LLP’s 7th Largest Position

Sarasin & Partners LLP raised its position in shares of Colgate-Palmolive Company (NYSE:CL) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,347,768 shares of the company’s stock after acquiring an additional 141,405 shares during the quarter. Colgate-Palmolive makes up about 3.6% of Sarasin & Partners LLP’s holdings, making the stock its 7th largest holding. Sarasin & Partners LLP owned 0.54% of Colgate-Palmolive worth $343,561,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in CL. Copia Wealth Management purchased a new stake in shares of Colgate-Palmolive during the third quarter worth approximately $29,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Colgate-Palmolive by 86.1% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 335 shares of the company’s stock valued at $30,000 after purchasing an additional 155 shares in the last quarter. Cloud Capital Management LLC purchased a new position in Colgate-Palmolive in the 3rd quarter valued at $30,000. Global Wealth Strategies & Associates boosted its stake in Colgate-Palmolive by 300.0% during the 4th quarter. Global Wealth Strategies & Associates now owns 400 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the last quarter. Finally, Kelleher Financial Advisors acquired a new stake in Colgate-Palmolive during the 3rd quarter worth $35,000. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Price Performance

CL stock opened at $85.14 on Friday. Colgate-Palmolive Company has a 52-week low of $74.54 and a 52-week high of $99.33. The company has a quick ratio of 0.54, a current ratio of 0.83 and a debt-to-equity ratio of 18.82. The stock has a market cap of $68.62 billion, a price-to-earnings ratio of 32.49, a price-to-earnings-growth ratio of 3.81 and a beta of 0.28. The business has a fifty day moving average of $91.01 and a two-hundred day moving average of $83.36.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, January 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.91 by $0.04. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.13 billion. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.91 EPS. As a group, research analysts anticipate that Colgate-Palmolive Company will post 3.75 earnings per share for the current year.

Colgate-Palmolive Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, April 20th. Colgate-Palmolive’s dividend payout ratio (DPR) is 79.39%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CL. Evercore upped their target price on shares of Colgate-Palmolive from $94.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, February 2nd. Barclays boosted their price target on shares of Colgate-Palmolive from $83.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Wall Street Zen upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group reissued a “buy” rating and issued a $100.00 target price on shares of Colgate-Palmolive in a research note on Friday, February 20th. Finally, JPMorgan Chase & Co. boosted their target price on Colgate-Palmolive from $93.00 to $97.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Eleven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.75.

Insider Activity at Colgate-Palmolive

In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $97.81, for a total value of $1,467,150.00. Following the sale, the chief operating officer owned 10,415 shares of the company’s stock, valued at $1,018,691.15. The trade was a 59.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Sally Massey sold 15,851 shares of the company’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $95.03, for a total value of $1,506,320.53. Following the transaction, the insider owned 13,751 shares in the company, valued at $1,306,757.53. This trade represents a 53.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 184,683 shares of company stock valued at $17,486,693 over the last 90 days. Insiders own 0.34% of the company’s stock.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.